Leiner to redistribute products
This article was originally published in The Tan Sheet
Executive SummaryFDA's Atlanta District Office grants Leiner Healthcare Products permission to begin distributing previously manufactured OTC products if a third-party quality assessment deems the products acceptable under FDA methodology. In an Oct. 22 Securities and Exchange Commission filing, the Carson, Calif.-based firm says it will begin re-distributing a portion of its inventory in December. Leiner suspended its U.S. OTC production and distribution March 20 and initiated a voluntary recall in April after FDA found GMP discrepancies at the firm's Fort Mill, S.C., facility (1"The Tan Sheet" Sept. 24. 2007, p. 12)
You may also be interested in...
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.